{"id":"NCT02954848","sponsor":"Takeda","briefTitle":"Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 10 mg Once-daily in the Treatment of Non-Erosive Gastroesophageal Reflux Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-15","primaryCompletion":"2018-02-25","completion":"2018-02-26","firstPosted":"2016-11-04","resultsPosted":"2019-08-02","lastUpdate":"2019-08-02"},"enrollment":484,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-erosive Gastroesophageal Reflux Disease"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"TAK-438 10 mg","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"TAK-438 10 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of oral TAK-438 10 mg once-daily in the treatment of non-erosive gastroesophageal reflux disease (NERD).","primaryOutcome":{"measure":"Percentage of Days Without Symptoms of Heartburn","timeFrame":"Up to Week 4","effectByArm":[{"arm":"Placebo","deltaMin":61.5,"sd":null},{"arm":"TAK-438 10 mg","deltaMin":72.55,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0643"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":30,"countries":["Japan"]},"refs":{"pmids":["31770139"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":245},"commonTop":["Viral upper respiratory tract infection"]}}